BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Us2.ai receives FDA clearance for Us2.v2,transforming cardiovascular ultrasound analysis
News | 04. 04. 2024
Us2.ai
Singapore – April 5, 2024 – Us2.ai, a leading MedTech firm backed by prominent investors including IHH Healthcare, Heal Partners, Peak XV Partners (formerly Sequoia India) and EDBI, announces FDA clearance for Us2.v2, featuring 45 automated echo parameters, including strain analysis, marking a significant stride in medical innovation.
